Acquired Hemophilia in an Elderly Patient with Non-Small Cell Lung Cancer: a Case Report
Open Access
- 23 November 2022
- journal article
- case report
- Published by Springer Science and Business Media LLC in SN Comprehensive Clinical Medicine
- Vol. 5 (1), 1-4
- https://doi.org/10.1007/s42399-022-01330-x
Abstract
Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. We report here a case of AHA that occurred in the Department of Medicina D’Urgenza in Sant’Andrea Hospital in a patient with previous diagnosis of NSLC. The aim of this article is to allow a more comprehensive knowledge of AHA that both for the rarity and the poor literature is underdiagnosed; for all these reasons, it is important that different specialists, like emergency specialists, experts in internal medicine, hematologists, and oncologists, acquire a more complete knowledge of the clinical and laboratory features of this disease, allowing an early diagnosis crucial for the evolution of the coagulopathy.Keywords
Funding Information
- Università degli Studi di Roma La Sapienza
This publication has 7 references indexed in Scilit:
- The first case of acquired hemophilia A associated with SARS‐CoV‐2 infectionAmerican Journal of Hematology, 2020
- International recommendations on the diagnosis and treatment of acquired hemophilia AHaematologica, 2020
- Acquired hemophilia A: a review of recent data and new therapeutic optionsHematology, 2017
- Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon.2017
- Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) RegistryBlood, 2012
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012
- Early treatment with recombinant factor VIIa results in greater efficacy with less productEuropean Journal of Haematology, 1998